Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Related Citations for PubMed (Select 23656439)

1.

Effect of clarithromycin in experimental empyema by multidrug-resistant Pseudomonas aeruginosa.

Tsovolou EC, Tzepi IM, Spyridaki A, Tsaganos T, Karagianni V, Menenakos E, Liakou P, Sabracos L, Zografos G, Giamarellos-Bourboulis EJ.

APMIS. 2014 Jan;122(1):68-75. doi: 10.1111/apm.12094. Epub 2013 May 8.

PMID:
23656439
2.

Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa.

Giamarellos-Bourboulis EJ, Antonopoulou A, Raftogiannis M, Koutoukas P, Tsaganos T, Tziortzioti V, Panagou C, Adamis T, Giamarellou H.

BMC Infect Dis. 2006 Feb 21;6:31.

3.

Impact of multidrug resistance on experimental empyema by Pseudomonas aeruginosa.

Giamarellos-Bourboulis EJ, Tzepi I, Tsovolou I, Spyridaki A, Tsaganos T, Vaki I, Kotsaki A, Polychronopoulos V.

Respiration. 2011;82(1):46-53. doi: 10.1159/000326893. Epub 2011 Apr 28.

PMID:
21525725
4.

Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa.

Giamarellos-Bourboulis EJ, Adamis T, Laoutaris G, Sabracos L, Koussoulas V, Mouktaroudi M, Perrea D, Karayannacos PE, Giamarellou H.

Antimicrob Agents Chemother. 2004 Jan;48(1):93-9.

5.

Intravitreal piperacillin/tazobactam in the management of multidrug-resistant Pseudomonas aeruginosa endophthalmitis.

Pathengay A, Mathai A, Shah GY, Ambatipudi S.

J Cataract Refract Surg. 2010 Dec;36(12):2210-1. doi: 10.1016/j.jcrs.2010.09.013. No abstract available.

PMID:
21111328
6.

The efficacy of piperacillin/tazobactam in experimental Pseudomonas aeruginosa endophthalmitis: a histopathological and microbiological evaluation.

Ozkiris A, Evereklioglu C, Esel D, Akgün H, Göktas S, Erkiliç K.

Curr Eye Res. 2005 Jan;30(1):13-9.

PMID:
15875360
7.

Clarithromycin is an effective immunomodulator in experimental pyelonephritis caused by pan-resistant Klebsiella pneumoniae.

Giamarellos-Bourboulis EJ, Tziortzioti V, Koutoukas P, Baziaka F, Raftogiannis M, Antonopoulou A, Adamis T, Sabracos L, Giamarellou H.

J Antimicrob Chemother. 2006 May;57(5):937-44. Epub 2006 Mar 20.

8.

Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.

Mimoz O, Elhelali N, Léotard S, Jacolot A, Laurent F, Samii K, Petitjean O, Nordmann P.

J Antimicrob Chemother. 1999 Jul;44(1):91-7.

9.

Immunomodulatory effect of three-day continuous administration of clarithromycin for experimental sepsis due to multidrug-resistant Pseudomonas aeruginosa.

Baziaka F, Giamarellos-Bourboulis EJ, Raftogiannis M, Adamis T, Tziortzioti V, Sabracos L, Chrisofos M, Koutoukas P, Giamarellou H, Douzinas EE.

J Chemother. 2008 Feb;20(1):63-8.

PMID:
18343746
11.

Piperacillin/tazobactam-heteroresistant Pseudomonas aeruginosa from urinary infection, successfully treated by piperacillin/tazobactam.

Pournaras S, Ikonomidis A, Neou E, Kantzanou M, Maniatis AN, Tsakris A.

J Antimicrob Chemother. 2008 Mar;61(3):757-8. doi: 10.1093/jac/dkm528. Epub 2008 Jan 15. No abstract available.

12.

Clarithromycin modulates immune responses in experimental peritonitis.

Atmatzidis S, Koutelidakis I, Chatzimavroudis G, Louis K, Pistiki A, Roditis K, Atmatzidis K, Giamarellos-Bourboulis EJ.

Int J Antimicrob Agents. 2011 Apr;37(4):347-51. doi: 10.1016/j.ijantimicag.2010.11.037. Epub 2011 Feb 25.

PMID:
21353492
13.

A comparison of intravitreal piperacillin/tazobactam with ceftazidime in experimental Pseudomonas aeruginosa endophthalmitis.

Ozkiriş A, Evereklioglu C, Akgün H, Eşel D, Caner F, Erkiliç K.

Exp Eye Res. 2005 Mar;80(3):361-7.

PMID:
15721618
14.

Protective effects of the combination of alpha-helical antimicrobial peptides and rifampicin in three rat models of Pseudomonas aeruginosa infection.

Cirioni O, Silvestri C, Ghiselli R, Orlando F, Riva A, Mocchegiani F, Chiodi L, Castelletti S, Gabrielli E, Saba V, Scalise G, Giacometti A.

J Antimicrob Chemother. 2008 Dec;62(6):1332-8. doi: 10.1093/jac/dkn393. Epub 2008 Sep 16.

15.

In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.

Bulik CC, Tessier PR, Keel RA, Sutherland CA, Nicolau DP.

Antimicrob Agents Chemother. 2012 Jan;56(1):544-9. doi: 10.1128/AAC.01752-10. Epub 2011 Nov 7.

16.

n-6 polyunsaturated fatty acids enhance the activities of ceftazidime and amikacin in experimental sepsis caused by multidrug-resistant Pseudomonas aeruginosa.

Giamarellos-Bourboulis EJ, Mouktaroudi M, Adamis T, Koussoulas V, Baziaka F, Perrea D, Karayannacos PE, Giamarellou H.

Antimicrob Agents Chemother. 2004 Dec;48(12):4713-7.

17.

Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients.

Harris AD, Perencevich E, Roghmann MC, Morris G, Kaye KS, Johnson JA.

Antimicrob Agents Chemother. 2002 Mar;46(3):854-8.

18.

Penetration of clarithromycin in experimental pleural empyema model fluid.

Liapakis IE, Light RW, Pitiakoudis MS, Karayiannakis AJ, Giamarellos-Bourboulis EJ, Ismailos G, Anagnostoulis S, Simopoulos CE, Bouros DE.

Respiration. 2005 May-Jun;72(3):296-300.

19.

In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.

Bui KQ, Banevicius MA, Nightingale CH, Quintiliani R, Nicolau DP.

J Antimicrob Chemother. 2000 Jan;45(1):57-62.

20.

Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.

Lodise TP Jr, Lomaestro B, Drusano GL.

Clin Infect Dis. 2007 Feb 1;44(3):357-63. Epub 2007 Jan 2.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk